CGT launch readiness: a two-part strategy series

Webinar 1: Early-stage planning for cell and gene therapy launch
September 29 | 11 AM–12 PM EST / 4-5 PM GMT
 

The cell and gene therapy space is advancing rapidly, and early, strategic planning is essential to navigate its unique complexities. From regulatory hurdles and evolving payer expectations to limited durability data and small patient populations, CGT developers are facing a distinct set of challenges that require careful groundwork well ahead of launch. 

Tap into Avalere Health’s market access, policy, and medical affairs expertise with an hour-long webinar that will cover the pre-launch strategies that set the foundation for long-term commercial success. 

What we’ll cover:

• Regulatory navigation and clinical trials: FDA pathways, EMA and APAC considerations, and clinical trial design for market access 

• Market access and reimbursement planning: Payer landscape assessments, early pricing strategy, and outcomes-based contracting 

• Evidence strategy and medical communications: Closing evidence gaps and building credible clinical narratives for HCPs and payers 

• Global policy considerations: HTA submissions, international access strategies, and equity of access 

• Patient and provider engagement: Journey mapping, advocacy group engagement, and site-of-care planning 

 

 

Webinar 2: Launch readiness and commercialization for cell and gene therapies
October 13 | 11 AM–12 PM EST / 4-5 PM GMT
 

Bringing a cell or gene therapy to market opens a new chapter of commercial and operational challenges. Durability uncertainty, access barriers, high treatment costs, and the ongoing need to demonstrate real-world value to payers, providers, and patients all require sustained strategic attention well beyond launch day. 

Join Avalere Health experts for a focused discussion on the commercialization strategies that help organizations across the CGT ecosystem maintain access and drive long-term product success. 

What we’ll cover: 

• Innovative contracting and reimbursement: Warranty programs, outcomes-based agreements, and tools for navigating payer negotiations 

• Real-world evidence generation: Post-market surveillance, long-term follow-up, and RWE to support ongoing coverage decisions 

• Global market access and policy: International strategies, HTA outcomes, and access equity considerations 

• Stakeholder communications and patient support: Tailored messaging for providers, payers, and patients, plus financial assistance and care coordination programs